Semaglutide FLOW Kidney and Heart Findings: What Patients Should Know 6th June 20266th June 2026 by Living Diabetes Editorial A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
Finerenone (Kerendia): Kidney and Heart Protection in Type 2 Diabetes 6th June 20262nd April 2026 by Living Diabetes Editorial Team Finerenone may reduce kidney and heart risks in CKD linked with type 2 diabetes. Learn who it is for, potassium monitoring, and cautions.
SGLT2 Inhibitors: Heart and Kidney Protection Beyond Glucose 3rd June 202621st March 2026 by Living Diabetes Editorial Team SGLT2 inhibitors can protect heart and kidney health in selected people, but they also need clear sick-day and safety guidance.
